Fragile X Syndrome - Pipeline Review, H2 2013


Naperville, IL -- (SBWIRE) -- 01/27/2014 -- Reportstack, provider of premium market research reports announces the addition of Fragile X Syndrome - Pipeline Review, H2 2013 market report to its offering
Fragile X Syndrome - Pipeline Review, H2 2013


, 'Fragile X Syndrome - Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Fragile X Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fragile X Syndrome. Fragile X Syndrome - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- A snapshot of the global therapeutic scenario for Fragile X Syndrome.
- A review of the Fragile X Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Fragile X Syndrome pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Fragile X Syndrome.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Fragile X Syndrome pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned

F. Hoffmann-La Roche Ltd.
Novartis AG
Paratek Pharmaceuticals, Inc.
Neuren Pharmaceuticals Limited
Cortex Pharmaceuticals, Inc.
Seaside Therapeutics, LLC
Snowdon Inc.
Marinus Pharmaceuticals, Inc.
Nexgenix Pharmaceuticals, LLC
aFraxis Inc.
Alcobra Ltd
Sage Therapeutics
Confluence Pharmaceuticals LLC
SMaRT Therapeutics, Inc.

To view the table of contents for this market research report please visit
Roger Campbell
United States
Ph: 888-789-6604